4 completed. 4 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 4 |
| Phase 1 | 1 | Completed 1 |
Follow FS 069: new trials by email Literature Review of FS 069 trials Research Report on FS 069
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Contrast-Enhanced Ultrasound for the Prediction of Bile Duct Cancer Response to Radioembolization Treatment Perflutren Protein-Type A Microspheres, Contrast-Enhanced Ultrasound - Intrahepatic Cholangiocarcinoma | Phase 2 | Completed | Thomas Jefferson University | 16 | 2021-12-14 | 2025-10-28 |
| Perflutren Protein-Type A Microspheres and Contrast-Enhanced Ultrasound in Improving Response to Radioembolization Therapy in Patients With Liver Cancer Yttrium-90 Microsphere Radioembolization, Perflutren Protein-Type A Microspheres, Dynamic Contrast-Enhanced Ultrasound Imaging - Hepatocellular Carcinoma | Phase 2 | Completed | Thomas Jefferson University | 104 | 2017-07-01 | 2026-01-02 |
| Two and Three Dimensional Contrast-enhanced Ultrasound for Screening of Renal Cell Carcinoma Recurrence Following Cryoablation Optison - Renal Cell Carcinoma | Phase 2 | Completed | Thomas Jefferson University | 53 | 2015-04-23 | 2025-05-04 |
| CeVUS With Intravesical Administration of OPTISON TM (Trademark) in Children OPTISON - Vesico-Ureteral Reflux | Phase 1 / Phase 2 | Completed | Kassa Darge | 31 | 2014-07-01 | 2018-11-27 |
Carcinoma, Hepatocellular (1) · Carcinoma, Renal Cell (1) · Cholangiocarcinoma (1) · Vesico-Ureteral Reflux (1)
Thomas Jefferson University (3) · Kassa Darge (1)
United States (4)
John Eisenbrey, PhD (1) · Kassa Darge, MD, PhD (1)
R01CA238241 (1), R21CA259750 (1)